{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:45Z","timestamp":1787960205103,"version":"build-2784847793"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2020,7,7]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">The rate of sudden cardiac death in the hemodialysis population exceeds that of the general population by &gt;20\u2010fold. Hemodialysis patients may be particularly susceptible to sudden cardiac death provoked by drug\u2010induced QT prolongation because of their substantial cardiovascular disease burden, exposure to electrolyte shifts during dialysis, and extensive polypharmacy. However, population\u2010specific data regarding the frequency and patterns of QT prolonging medication use are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">We conducted a descriptive drug utilization study using 3 administrative databases, the United States Renal Data System, MarketScan, and Medicare claims. We characterized the extent and patterns of QT prolonging medication use by adult hemodialysis patients and individuals without end\u2010stage kidney disease annually from 2012 to 2016. We also identified instances of high\u2010risk QT prolonging medication use among hemodialysis patients. In total, 338\u00a0515 hemodialysis patients and 40.7\u00a0million individuals without end\u2010stage kidney disease were studied. Annual utilization rates of QT prolonging medications with known torsades de pointes risk in hemodialysis patients were ~1.4 to ~2.5 times higher than utilization rates in individuals without end\u2010stage kidney disease. Hemodialysis patients with demographic and clinical risk factors for drug\u2010induced QT prolongation were exposed to medications with known torsades de pointes risk more often than patients without risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Hemodialysis patients use QT prolonging medications with known torsades de pointes risk more extensively than individuals without end\u2010stage kidney disease. Given the widespread use and instances of high\u2010risk prescribing, future studies evaluating the cardiac safety of these drugs in the hemodialysis population are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.120.015969","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T05:25:58Z","timestamp":1592976358000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End\u2010Stage Kidney Disease"],"prefix":"10.1161","volume":"9","author":[{"given":"Magdalene M.","family":"Assimon","sequence":"first","affiliation":[{"name":"University of North Carolina Kidney Center Division of Nephrology and Hypertension Department of Medicine University of North Carolina School of Medicine Chapel Hill NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Wang","sequence":"additional","affiliation":[{"name":"Cecil G. Sheps Center for Health Services Research University of North Carolina Chapel Hill NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Pun","sequence":"additional","affiliation":[{"name":"Division of Nephrology Department of Medicine Duke University School of Medicine Durham NC"},{"name":"Duke Clinical Research Institute Duke University Medical Center Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[{"name":"Section of Nephrology Selzman Institute for Kidney Health Baylor College of Medicine Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Flythe","sequence":"additional","affiliation":[{"name":"University of North Carolina Kidney Center Division of Nephrology and Hypertension Department of Medicine University of North Carolina School of Medicine Chapel Hill NC"},{"name":"Cecil G. Sheps Center for Health Services Research University of North Carolina Chapel Hill NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.01.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra000650"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh288"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000249"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2008.03.011"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039818"},{"key":"e_1_3_2_8_2","unstructured":"Woosley RK Heise CW Romero KA. QT Drugs List. AZCERT Inc. 1822 Innovation Park Dr. Oro Valley AZ 85755. 2019. Available at: www.Credi\u200bbleme\u200bds.org. Accessed July 10 2019."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi312"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.840568"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1129"},{"key":"e_1_3_2_12_2","first-page":"12","article-title":"Sudden cardiac death in nephrology: focus on acquired long qt syndrome","author":"Gussak I","year":"2007","unstructured":"Gussak I, Gussak HM. Sudden cardiac death in nephrology: focus on acquired long qt syndrome. Nephrol Dial Transplant. 2007;12\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018101032"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"e0155445","DOI":"10.1371\/journal.pone.0155445","article-title":"Electrocardiographic abnormalities and QTc interval in patients undergoing hemodialysis","author":"Nie Y","year":"2016","unstructured":"Nie Y, Zou J, Liang Y, Shen B, Liu Z, Cao X, Chen X, Ding X. Electrocardiographic abnormalities and QTc interval in patients undergoing hemodialysis. PLoS ONE. 2016;e0155445.","journal-title":"PLoS ONE"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22277"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781118949740"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9629(15)40678-0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx085"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000319591"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.019"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvw045"},{"key":"e_1_3_2_23_2","unstructured":"U. S. Food and Drug administration . Guidance for industry \u2013 S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Available at: https:\/\/www.fda.gov\/regul\u200batory-infor\u200bmatio\u200bn\/search-fda-guida\u200bnce-docum\u200bents\/s7b-noncl\u200binical-evalu\u200bation-poten\u200btial-delay\u200bed-ventr\u200bicular-repol\u200bariza\u200btion-qt-inter\u200bval-prolo\u200bngation. Accessed December 10 2019."},{"key":"e_1_3_2_24_2","unstructured":"U. S. Food and drug administration . E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs. Available at: https:\/\/www.fda.gov\/regul\u200batory-infor\u200bmatio\u200bn\/search-fda-guida\u200bnce-docum\u200bents\/e14-clini\u200bcal-evalu\u200bation-qtqtc-inter\u200bval-prolo\u200bngati\u200bon-and-proar\u200brhyth\u200bmic-poten\u200btial-non-antia\u200brrhyt\u200bhmic-0. Accessed December 10 2019."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12776"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000085057.63483.9b"},{"key":"e_1_3_2_27_2","unstructured":"Celexa\u00ae (citalopram hydrobromide) [package insert] . Irvine CA: Allergan USA Inc; 2017."},{"key":"e_1_3_2_28_2","unstructured":"Zofran\u00ae (ondansetron hydrochloride) [package insert] . East Hanover NJ: Novartis pharmaceuticals corporation; 2017."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192704"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1542-474X.2003.08211.x"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0101.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120533"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh280"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011607"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.006"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy060"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04571007"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.015969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:36:47Z","timestamp":1715585807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.015969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,7]]}},"alternative-id":["10.1161\/JAHA.120.015969"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.015969","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"2020-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e015969"}}